(Reuters) – Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca’s preventive respiratory syncytial virus (RSV) therapy.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswas)
